CD16/PD-L1 bi-specific aptamer for cancer immunotherapy through recruiting NK cells and acting as immunocheckpoint blockade

Hinrichs, 2014, Exploiting the curative potential of adoptive T-cell therapy for cancer, Immunol. Rev., 257, 56, 10.1111/imr.12132 Wang, 2020, CAR-NK for tumor immunotherapy: clinical transformation and future prospects, Cancer Lett., 472, 175, 10.1016/j.canlet.2019.11.033 Rezvani, 2017, Engineering natural killer cells for cancer immunotherapy, Mol. Ther., 25, 1769, 10.1016/j.ymthe.2017.06.012 Bonifant, 2016, Toxicity and management in CAR T-cell therapy, Mol. Ther. Oncolytics., 3, 16011, 10.1038/mto.2016.11 Ingegnere, 2019, Human CAR NK cells: a new non-viral method allowing high efficient transfection and strong tumor cell killing, Front. Immunol., 10, 957, 10.3389/fimmu.2019.00957 Davies, 2014, Opportunities and limitations of natural killer cells as adoptive therapy for malignant disease, Cytotherapy, 16, 1453, 10.1016/j.jcyt.2014.03.009 Childs, 2015, Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens, Nat. Rev. Drug Discov., 14, 487, 10.1038/nrd4506 Yang, 2019, Aptamer-engineered natural killer cells for cell-specific adaptive immunotherapy, Small, 15, e1900903, 10.1002/smll.201900903 Gasteiger, 2014, Interactions between innate and adaptive lymphocytes, Nat. Rev. Immunol., 14, 631, 10.1038/nri3726 Bald, 2020, The NK cell–cancer cycle: advances and new challenges in NK cell–based immunotherapies, Nat. Immunol., 21, 835, 10.1038/s41590-020-0728-z Siegler, 2018, Off-the-Shelf CAR-NK cells for cancer immunotherapy, Cell Stem Cell, 23, 160, 10.1016/j.stem.2018.07.007 Macdonald, 2018, EpCAM immunotherapy versus specific targeted delivery of drugs, Cancers, 10, 19, 10.3390/cancers10010019 Carrega, 2014, CD56 bright perforin low noncytotoxic human NK cells are abundant in both healthy and neoplastic solid tissues and recirculate to secondary lymphoid organs via afferent lymph, J. Immunol., 192, 3805, 10.4049/jimmunol.1301889 Ku, 2015, Nucleic acid aptamers: an emerging tool for biotechnology and biomedical sensing, Sensors, 15, 16281, 10.3390/s150716281 Fang, 2010, Aptamers generated from cell-SELEX for molecular medicine: a chemical biology approach, Acc. Chem. Res., 43, 48, 10.1021/ar900101s Zhou, 2017, Aptamers as targeted therapeutics: current potential and challenges, Nat. Rev. Drug Discov., 16, 181, 10.1038/nrd.2016.199 Morita, 2018, Aptamer therapeutics in cancer: current and future, Cancers, 10, 80, 10.3390/cancers10030080 Hori, 2018, Current advances in aptamers for cancer diagnosis and therapy, Cancers, 10, 9, 10.3390/cancers10010009 Ohuchi, 2012, Cell-Selex technology, Biores. Open Access, 1, 265, 10.1089/biores.2012.0253 Zhou, 2016, Aptamers: a promising chemical antibody for cancer therapy, Oncotarget, 7, 13446, 10.18632/oncotarget.7178 Bai, 2020, Self-assembled multivalent aptamer nanoparticles with potential CAR-like characteristics could activate T cells and inhibit melanoma growth, Mol. Ther. Oncolytics, 17, 9, 10.1016/j.omto.2020.03.002 Lao, 2015, Aptamer nanomedicine for cancer therapeutics: barriers and potential for translation, ACS Nano, 9, 2235, 10.1021/nn507494p Shu, 2021, Stoichiometry of multi-specific immune checkpoint RNA Abs for T cell activation and tumor inhibition using ultra-stable RNA nanoparticles, Mol. Ther. Nucleic Acid, 24, 426, 10.1016/j.omtn.2021.03.007 Boltz, 2011, Bi-specific aptamers mediating tumor cell lysis, J. Biol. Chem., 286, 21896, 10.1074/jbc.M111.238261 Tang, 2007, Selection of aptamers for molecular recognition and characterization of cancer cells, Anal. Chem., 79, 4900, 10.1021/ac070189y McNamara, 2008, Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice, J. Clin. Invest., 118, 376, 10.1172/JCI33365 Li, 2019, Novel bispecific aptamer enhances immune cytotoxicity against MUC1-positive tumor cells by MUC1-CD16 dual targeting, Molecules, 24, 478, 10.3390/molecules24030478 Soldevilla, 2016, MRP1-CD28 bi-specific oligonucleotide aptamers: target costimulation to drug-resistant melanoma cancer stem cells, Oncotarget, 7, 23182, 10.18632/oncotarget.8095 Ganji, 2016, Aptamers: new arrows to target dendritic cells, J. Drug Target., 24, 1, 10.3109/1061186X.2015.1041962 Yang, 2020, Circular bispecific aptamer-mediated artificial intercellular recognition for targeted T cell immunotherapy circular bispecific aptamer-mediated artificial intercellular recognition for targeted T cell immunotherapy, ACS Nano, 14, 9562, 10.1021/acsnano.9b09884 Vandghanooni, 2018, Bispecific therapeutic aptamers for targeted therapy of cancer: a review on cellular perspective, J. Mol. Med., 96, 885, 10.1007/s00109-018-1669-y Benson, 2010, The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody, Blood, 116, 2286, 10.1182/blood-2010-02-271874 Chen, 2015, Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future, J. Clin. Invest., 125, 3384, 10.1172/JCI80011 Prodeus, 2015, Targeting the PD-1/PD-L1 immune evasion Axis with DNA aptamers as a novel therapeutic strategy for the treatment of disseminated cancers, Mol. Ther. Nucleic Acids, 4, e237, 10.1038/mtna.2015.11 Yu, 2015, A novel approach of targeted immunotherapy against adenocarcinoma cells with nanoparticles modified by CD16 and MUC1 aptamers, J. Nanomater., 2015, 316968, 10.1155/2015/316968 Topalian, 2012, Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity, Curr. Opin. Immunol., 24, 207, 10.1016/j.coi.2011.12.009 Di Giusto, 2006, Multitasking by multivalent circularDNA aptamers, ChemBioChem, 7, 535, 10.1002/cbic.200500316 Nishino, 2017, Monitoring immune-checkpoint blockade: response evaluation and biomarker development, Nat. Rev. Clin. Oncol., 14, 655, 10.1038/nrclinonc.2017.88 Pardoll, 2012, The blockade of immune checkpoints in cancer immunotherapy, Nat. Rev. Cancer, 12, 252, 10.1038/nrc3239 Lai, 2016, A novel PD-L1-targeting antagonistic DNA aptamer with antitumor effects, Mol. Ther. Nucleic Acids, 5, e397, 10.1038/mtna.2016.102 Zhang, 2020, Equipping natural killer cells with specific targeting and checkpoint blocking aptamers for enhanced adoptive immunotherapy in solid tumors, Angew. Chem., 132, 12120, 10.1002/ange.202002145 Dong, 2019, The mechanism of anti-PD-L1 antibody efficacy against PD-L1-negative tumors identifies NK cells expressing PD-L1 as a cytolytic effector, Cancer Discov., 9, 1422, 10.1158/2159-8290.CD-18-1259 Poznanski, 2021, Expanded human NK cells from lung cancer patients sensitize patients' PDL1-negative tumors to PD1-blockade therapy, J. Immunother. Cancer, 9, e001933, 10.1136/jitc-2020-001933